• SENSEX
    NIFTY 50
Healthcare

A Rs 3,800 cr mcap gain for a Rs 90 cr revenue pop: Is Glenmark's favipiravir rally too much?

Updated : June 23, 2020 03:50 PM IST

Glenmark shares rose about 30 percent today, adding Rs 3,800 crore in mcap after it received a nod to launch favipiravir.
Brokerages, however, see the revenue opportunity from the drug at Rs 25-90 crore.
A Rs 3,800 cr mcap gain for a Rs 90 cr revenue pop: Is Glenmark's favipiravir rally too much?

You May Also Like

Live TV
Advertisement